Introduction
The proto-oncogene B cell lymphoma 6 (BCL6), a critical transcriptional repressor for germinal center (GC) reaction, 1 is a frequently targeted partner for chromosomal translocations (CT) associated with various lymphomas such as diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). [1] [2] [3] [4] Reciprocal CTs between the immunoglobulin (Ig) gene locus on 14q32
and the BCL6 gene on 3q27, e.g., t(3;14)(q27;q32), are found in a significant portion of DLBCL and FL, 1 and they strongly implicate Ig/BCL6 CT in the development of these lymphomas. Ig/BCL6 CT primarily occurs between the Ig switch regions and the non-coding exon1-intron1 region of the BCL6 gene [2] [3] [4] [5] [6] , presumably mediated by the similar mechanism for Ig class switch recombination (Ig CSR). 7 As a result, expression of the BCL6 from the translocated locus comes under the transcriptional control of Ig region promoter/enhancer, a genetic alteration known as promoter substitution. 6 The replacement of the natural BCL6 promoter, which is subjected to tight control during GC reaction , 8 by the Ig promoters/enhancers results in dysregulation of BCL6 expression. 6 As BCL6 expression is critical for B cell proliferation, differentiation and survival in GC, the deregulated BCL6 expression is believed to contribute to B cell malignant transformation for a subgroup of DLBCL and FL. [6] [7] [8] [9] The long-held speculation that deregulated BCL6 expression driven by Ig promoters/enhancers plays an important role in B cell malignant transformation during lymphomagenesis gains support from recent data showing in mice models that Ig promoter/enhancer controlled BCL6 expression promotes lymphomagenesis. 10, 11 Although Ig/BCL6 CT has been implicated in the lymphomagenesis as related to DLBCL and FL, it is not clear what the exact role of the CT is during the malignant transformation, and whether the Ig/BCL6 CT per se is sufficient to lead to the malignant transformation in the context of human B cells. These important questions regarding the biology of the Ig/BCL6 translocated cells prior to their malignant transformation have not been previously addressed because of the lack of an assay capable of detecting and measuring such rare Ig/BCL6 translocated cells in their preFor personal use only. on . by guest www.bloodjournal.org From cancerous stages. We reasoned that one way to gain insight into the role of Ig/BCL6 translocation in B cell malignant transformation and lymphomagenesis is to examine the Ig/BCL6 translocations prior to malignant transformation. In this paper, we report the results of using a novel system to detect and measure rare Igµ/BCL6 CT events in mixed cell populations and to characterize the CT cells and quantify their frequencies in lymphoid tissues of otherwise healthy humans.
Materials and Methods

Cell and cell lines
Human tonsils and spleens were collected following tonsillectomy or splenectomy performed at the UCLA Center for Health Sciences and Kaiser Permanente Medical Center at Panorama City, California, after obtaining appropriate Institutional Review Board approval. Human peripheral mononuclear cells (PBMCs) from healthy donors were obtained from the Core Virology Laboratory of the Jonsson Cancer Center at UCLA. Diffuse large B cell lymphoma tissues were previously collected from patients with this diagnosis and stored. Informed consent was provided according to the Declaration of Helsinki. The human B cell line Ramos 2G6 was purchased from ATCC. 12, 13 BL-2 and DG75 cells were provided by Dr. Q. Pan-Hammarstrom (Karolinska Institute, Sweden), 14 and CL-01 was provided by Drs. P. Casali (UC Irvine, CA) and A. Cerutti (Cornell University, NY). 15 All the cells and cell lines were cultured or maintained in the complete RPMI 1640, as described previously.
13
Cell isolation procedures
Tonsillar B cells were purified from tonsil mononuclear cells as described previously. 
RT-PCR
Total RNA was extracted by Trizol reagent (Invitrogen) as described. 13 Total RNA (1
RNA from a given number of cells as indicated, was reverse-transcribed to cDNA by MMLV transcriptase priming with oligo-dT 15 , as previously described. 13 Detection of the chimeric Iµ-BCL6E2 and BCL6E1-Cµ1 transcripts was performed with a nested PCR protocol with regular Taq polymerase in the presence of 2.5 mM of MgCl 2 (Promega Inc, Madison, WI). 13 The first round For personal use only. on . by guest www.bloodjournal.org From (5'-AATTGAGCTCTGTTGATTCTTAG-3') and 3' primer CHµ1.2 (CCTCTCAGGACTGATGGGAAGC-3') were used for the first round, and 5' primer BCL6E1 (5'-GTTCTTAGAAGTGGTGATGCAAG-3') and 3' primer CHµ1.0 (5'-TGGAGGAGAAAGTGATGGAGTCG-3') for the second round PCR. To monitor the cDNA loading, GAPDH was simultaneously amplified with the first round PCR with a forward primer (5'-TGAAGGTCGGAGTCAACGGATTTGGT-3') and a reverse primer (5'CCATGTAGTTGAGGTCAATGAA -3') that amplify a 120 bp product. For detection of Igµ germline transcripts (Iµ-Cµ transcripts), the primers Iµ3.1 and Cµ1.1 (5'-TGCTCTGATGTCAGAGTTGTTC-3') were used to amplify a 255 bp product. For BCL6 transcripts, the primers BCL6 E1 and BCL6-3C4.1 were used to amplify a 147 bp product. The PCR product was electrophoresed with 2% TBE agarose gel. To prevent possible cross contamination, cell manipulation, RNA preparation and cDNA synthesis were performed in a different location from that of PCR product analysis. An aliquot of PCR master mix without template DNA was always included as negative control for both first and second round PCR.
For quantification of chimeric Iµ-BCL6E2 transcript expressing cells, total tonsillar cells were two-fold serially diluted in duplication starting at 4X10 6 cells. The RNA prepared from each cell dilution was subjected to RT reaction and PCR with the method described above. The end dilution with at least one positive signal from the duplicates was scored as positive and arbitrarily defined as one translocation event. The translocation frequency was normalized to event (s) in every 1X10 6 total tonsillar cells.
Amplification, cloning and sequencing of the Ig/BCL6 translocation fragments.
Genomic DNA was prepared from DG75 cell line, DLBCL cells, tonsil and spleen B cells, and isolated cell subpopulations using DNA extraction kits (Promega), as previously described. 13 DNA (400 ng/reaction) was amplified using an expanded PCR kit (Roche Applied Science, 18 and the exon 1-intron 1 region of the BCL6 gene (~10 Kb) 5, 6 should uniformly produce the chimeric Iµ-BCL6 transcripts derived from the splicing of the Iµ exon to the exon 2 of the BCL6 gene, 6 we reasoned that such chimeric transcripts could serve as a marker for the rare Igµ/BCL6 translocation events that we predict occurs in heterogeneous cell populations prior to their malignant transformation.
To test this possibility, we established a nested RT-PCR assay to detect the expression of the chimeric Iµ-BCL6 transcripts. As shown in Figure 1 Sequencing revealed that in the BCL6E1-Cµ transcripts, the BCL6 exon 1 sequence is accurately spliced to the splicing acceptor site of the exon 1 of the Cµ gene (Cµ1) (supplemental Figure S1B ). This result demonstrates that the chimeric BCL6E1-Cµ1 transcripts, the products of the other side of reciprocal Ig/BCL6 translocations in chromosome d (14) , are present in human tonsillar B cells.
Co-expression of chimeric Iµ-BCL6E2 and BCL6E1-Cµ1 transcripts.
The reciprocal nature of Ig/BCL6 translocations theoretically should lead the CT cells to express both chimeric Iµ-BCL6E2 and BCL6E1-Cµ1 transcripts in the same cells. To determine whether these two types of chimeric transcripts are simultaneously expressed, we examined their expression in the same cell populations. As shown in Figure 2A , the BCL6E1-Cµ1 transcripts were (Figure 2A ). These results indicate that both types of chimeric transcripts are correlatively expressed in the same cell subpopulations. Comparison of the assay sensitivities between the Iµ-BCL6E2 and BCL6E1-Cµ1 transcripts revealed that the assay sensitivity for the Iµ-BCL6E2 transcripts was about 9-fold higher than that for the BCL6E1-Cµ1 transcripts ( Figure 2B ). Therefore, we chose the assay for Iµ-BCL6E2 transcripts as the primary detection method in further studies. To further analyze the Igµ/BCL6 translocation events in normal human lymphoid tissues and in circulation, we investigated the distribution of the Iµ-BCL6E2 transcripts in human lymphoid tissues and PBMC. We detected Iµ-BCL6E2 transcripts in 39 out of 41 (96%) randomly collected human tonsils ( Figure 5A and Table 1 ) and 3 out of 3 (100%) human spleens ( Figure 5B ) by using a total of 1X10 6 tonsillar or splenic cells. T32 tonsil was the only sample that has been confirmed to be negative for both types of chimeric transcripts from both total tonsil cells and CD38 + B cells through multiple tests ( Figure 2A and Table 1 ). We could not confirm the negative Iµ-BCL6 expression results for T9 ( Figure 5A ) with CD38 + B cells, as it was a previously frozen sample.
These results show that Igµ/BCL6 translocated cells are present in lymphoid tissues in the vast majority, if not all, of otherwise normal individuals. However, peripheral blood mononuclear cells (PBMC) from fourteen donors were negative when 1-2X10 6 cells were analyzed for Iµ-BCL6 transcripts ( Figure 5C )(see discussion).
Analysis of magnetic bead selected cells was undertaken to define the distribution of Iµ-BCL6E2 transcripts with B cells subpopulations. Iµ-BCL6E2 transcripts were consistently detected in CD19 + , CD38 + , and IgD -B cell populations, as well as in total tonsillar cells, but not in CD3 + or CD209 + , tonsillar cell populations ( Figure 5D and 
Frequency estimation of the Igµ/BCL6 translocation cells in human tonsils.
We next sought to define the sensitivity of our assay for the quantitative measurement of chimeric transcripts as a biomarker for Ig/BCL6 translocation in mixed cell populations. As shown in Figure 6A , the assay could reliably detect chimeric Iµ-BCL6E2 transcript in the RNA equivalent Figure 6B , where the frequency was 1 event for every 10 6 tonsillar cells.
Hence, one CT "event" is at least one (or more than one) CT cell in the given cell population. It is generally believed that a CT is a critical minimum factor in the development of many types of leukemias/lymphomas, as many such CTs are strongly associated with specific leukemias/ lymphomas. 21 However, several types of CTs per se are known to be insufficient to result in full lymphomagenesis, e.g., Ig/BCL2 [t(14;18)(q32;q21)], 22 Ig/c-myc [t(8;14)(q24;q32)], 23 and NMP/ALK [t(2;5)(p23;q35)], 24 in humans and various types of CT in mice. 21 This latter data supports a "two-hit" hypothesis, 25 in which another factor(s), including genetic or epigenetic alterations in addition to the CT per se, is required for malignant transformation in these specific CT-associated lymphomas. However, one cannot simply extrapolate this outcome to other lymphoma-associated CTs and, especially, in those involved in Ig/BCL6 CT that are frequently
CT cells in 10 6 cells, we were able to identify and to quantify the frequencies of these CT cells in human tonsils, spleen and blood. Essentially, all tonsil and spleen samples demonstrated the presence of the chimeric transcripts indicative of the Igµ/BCL6 CT, while such cells were not found in PMBC. Therefore we showed that Ig/BCL6 CT cells exist in human lymphoid tissues of otherwise healthy individuals. Our data also show that the frequent occurrence of an Ig/BCL6 CT in human lymphoid tissues is not sufficient to result in malignant transformation. This is of particular interest in that the deregulated BCL6 expression driven by an Iµ-promoter is not sufficient to lead to lymphomagenesis in the context of human B cells, while it is able to promote DLBCL-like pathology in a transgenic mouse model.
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The association of Ig/BCL6 CT cells with GC phenotypes suggests that the CT occurs at the GC stage of B cell development, e.g., that these CT cells are the products of the GC reaction. This is consistent with the GC-origin of DLBCL. Indeed, the machinery for Ig SHM and CSR, two major genetic alteration events for antibody diversification that occur during GC reactions, 26, 27 has been implicated in the generation of BCL6 mutations 28 and in Ig/BCL6 translocations (this study), as they are characteristics of the activation induced cytidine deaminase (AID)-dependent Ig SHM and Ig CSR. 6, 28, 29 Therefore, both BCL6 SHM and Ig/BCL6
CT are likely the byproducts reminiscent of the GC reactions mediated by the machinery for Ig SHM and CSR.
The fate of the cells that carry the observed Ig/BCL6 CT remains to be fully explored and will be of great interest in terms of the potency as the precancerous cells for the subsequent malignant transformation. Those CT cells that do not express B cell receptors (BCR) are not expected to survive the GC selection, since CT-associated lymphomas with GC origin usually express BCR and the CT cells are predominantly involved in the non-productively rearranged Ig alleles. 7, 30 Even though the number of Ig/BCL6 CT cells will survive through GC selection is not 
